Analysts Anticipate Catalyst Pharmaceuticals Inc (CPRX) to Post -$0.06 Earnings Per Share
Equities research analysts forecast that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will report earnings per share of ($0.06) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Catalyst Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.03 and the lowest estimate coming in at ($0.10). Catalyst Pharmaceuticals also reported earnings per share of ($0.06) during the same quarter last year. The company is expected to announce its next quarterly earnings report on Tuesday, August 6th.
On average, analysts expect that Catalyst Pharmaceuticals will report full-year earnings of ($0.21) per share for the current financial year, with EPS estimates ranging from ($0.40) to $0.09. For the next year, analysts anticipate that the company will post earnings of $0.32 per share, with EPS estimates ranging from $0.05 to $0.92. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Monday, May 13th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.12. The firm had revenue of $12.45 million for the quarter, compared to analyst estimates of $2.40 million. During the same period in the prior year, the company earned ($0.06) earnings per share.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SEI Investments Co purchased a new position in Catalyst Pharmaceuticals in the first quarter valued at approximately $572,000. Geode Capital Management LLC lifted its stake in Catalyst Pharmaceuticals by 7.8% in the first quarter. Geode Capital Management LLC now owns 1,146,422 shares of the biopharmaceutical company’s stock valued at $5,846,000 after purchasing an additional 82,654 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Catalyst Pharmaceuticals by 8.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 226,188 shares of the biopharmaceutical company’s stock valued at $1,154,000 after purchasing an additional 17,784 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Catalyst Pharmaceuticals by 5.8% in the first quarter. The Manufacturers Life Insurance Company now owns 67,107 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 3,702 shares during the last quarter. Finally, Kennedy Capital Management Inc. purchased a new position in Catalyst Pharmaceuticals in the first quarter valued at approximately $5,099,000. 47.85% of the stock is owned by hedge funds and other institutional investors.
Shares of CPRX stock traded up $0.41 on Wednesday, hitting $3.54. 5,301,400 shares of the stock were exchanged, compared to its average volume of 2,140,035. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.08 and a quick ratio of 5.80. The stock has a market capitalization of $325.02 million, a P/E ratio of -10.73 and a beta of 2.43. Catalyst Pharmaceuticals has a fifty-two week low of $1.85 and a fifty-two week high of $6.16.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
See Also: What is Cost of Goods Sold (COGS)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.